(Q33933206)

30 July 2017

title

Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy (English)

1 reference

30 July 2017

1 reference

Chari RV

1

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 April 1998

1 reference

Advanced Drug Delivery Reviews

30 July 2017

published in

1 reference

30 July 2017

volume

31

1 reference

30 July 2017

issue

1-2

1 reference

30 July 2017

page(s)

89-104

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Humanization of murine monoclonal antibodies through variable domain resurfacing

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Epidermal Growth Factor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Melanotropin–daunomycin conjugate shows receptor-mediated cytotoxicity in cultured murine melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Hormone-drug conjugates.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Preparation and characterization of interleukin-2-gelonin conjugates made using different crosslinking reagents

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Target-selective cytotoxicity of methotrexate conjugated with monoclonal anti-MM46 antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Biodistribution and tumour localisation of a daunomycin-monoclonal antibody conjugate in nude mice with human tumour xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Immunochemotherapy of human colon carcinoma xenografts in nude mice using combinations of idarubicin-monoclonal antibody conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Antibody-targeted drugs for the therapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

The linkage of cytotoxic drugs to monoclonal antibodies for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Preparation and in vitro cytotoxicity of a methotrexate-anti-MM46 monoclonal antibody conjugate via an oligopeptide spacer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Cis-aconityl spacer between daunomycin and macromolecular carriers: A model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Pharmacokinetics and mechanism of action of a doxorubicin-monoclonal antibody 9.2.27 conjugate directed to a human melanoma proteoglycan

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

p-Benzylthiocarbamoyl-aspartyl-daunorubicin-substituted polytrisacryl. A new drug acid-labile arm-carrier conjugate

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Inhibition of human renal cancer by monoclonal-anti-body-linked methotrexate in an ascites tumor model.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Monoclonal antibody drug conjugates for site-directed cancer chemotherapy: preclinical pharmacology and toxicology studies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Preparation and functional evaluation of new doxorubicin immunoconjugates containing an acid-sensitive linker on small-cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Stabilization of chimeric BR96-doxorubicin immunoconjugate

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Inhibition of human tumor growth in nude mice by a conjugate of doxorubicin with monoclonal antibodies to epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

In vivo efficacy of monoclonal antibody-drug conjugates of three different subisotypes which bind the human tumor-associated antigen defined by the KS1/4 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Monoclonal antibody KS1/4-methotrexate immunoconjugate studies in non-small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Disposition of a murine monoclonal antibody vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Eradication of large colon tumor xenografts by targeted delivery of maytansinoids

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Antibody conjugates with morpholinodoxorubicin and acid cleavable linkers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

Antimitotic Activity of the Potent Tumor Inhibitor Maytansine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

The chemistry, mechanism of action and biological properties of CC-1065, a potent antitumor antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900095-1

7 January 2021

10.1016/S0169-409X(97)00095-1

Identifiers

DOI

1 reference

30 July 2017

1 reference